Acquisitions Preliminaty Purchase Price Allocation (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2024	Jun. 30, 2024	Dec. 31, 2023	Sep. 26, 2023
Business Acquisition [Line Items]
Goodwill		$ 6,227.4	$ 6,219.2
Reata Pharmaceuticals, Inc
Business Acquisition [Line Items]
Cash and cash equivalents		267.3
Accounts receivable		15.9
Inventory		1,259.0		$ 1,300.0
Other current assets		53.6
Operating lease assets		121.2		121.2
Accrued expense and other(1)		(106.4)
Debt payable		(159.9)
Contingent payable to Blackstone		(300.0)
Deferred tax liabilities		(916.5)
Operating lease liabilities		(151.8)		(151.8)
Other assets and liabilities, net		(2.5)
Total identifiable net assets		6,719.9
Goodwill		473.5		473.5
Total assets acquired and liabilities assumed		7,193.4
Adjustment, accrued expense and other	$ 4.9
Deferred tax liability	4.1
Adjustment, goodwill	$ 9.0
Reata Pharmaceuticals, Inc | Completed technology for SKYCLARYS (U.S.)
Business Acquisition [Line Items]
Intangible assets:		4,200.0		4,200.0
Reata Pharmaceuticals, Inc | In-process research and development
Business Acquisition [Line Items]
Intangible assets:		2,300.0		2,300.0
Reata Pharmaceuticals, Inc | Priority review voucher
Business Acquisition [Line Items]
Intangible assets:		100.0		100.0
Reata Pharmaceuticals, Inc | Other clinical programs
Business Acquisition [Line Items]
Intangible assets:		$ 40.0		$ 40.0